Kalyan Das

Dr. Kalyan Das

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Journal of Molecular Biology
Verified
Journal Article
Closed access
SSStefan Sarafianos
Stefan Sarafianos
BMBruno Marchand
Bruno Marchand
KDKalyan Das
Kalyan Das
DHDaniel M. Himmel
Daniel M. Himmel
MPMichael A. Parniak
Michael A. Parniak
EAEddy Arnold
Eddy Arnold


15 March 2001 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SSStefan Sarafianos
Stefan Sarafianos
KDKalyan Das
Kalyan Das
CTChris Tantillo
Chris Tantillo
ACArthur D. Clark
Arthur D. Clark
JDJianping Ding
Jianping Ding
EAEddy Arnold
Eddy Arnold
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

5 February 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KDKalyan Das
Kalyan Das
JBJoseph D. Bauman
Joseph D. Bauman
ACArthur D. Clark
Arthur D. Clark
YFYulia V. Frenkel
Yulia V. Frenkel
PLPaul J. Lewi
Paul J. Lewi
EAEddy Arnold
Eddy Arnold
TMC278 is a diarylpyrimidine (DAPY) nonnucleoside reverse transcriptase inhibitor (NNRTI) that is highly effective in treating wild-type and drug-resistant HIV-1 infections in clinical trials at relatively low doses (∼25–75 mg/day). We have determined the structure of wild-type HIV-1 RT complexed with TMC278 at 1.8 Å resolution, using an RT crystal form engineered by systematic RT mutagenesis. This high-resolution structure reveals that the cyanovinyl group of TMC278 is positioned in a hydrophobic tunnel connecting the NNRTI-binding pocket to the nucleic acid-binding cleft. The crystal structures of TMC278 in complexes with the double mutant K103N/Y181C (2.1 Å) and L100I/K103N HIV-1 RTs (2.9 Å) demonstrated that TMC278 adapts to bind mutant RTs. In the K103N/Y181C RT/TMC278 structure, loss of the aromatic ring interaction caused by the Y181C mutation is counterbalanced by interactions between the cyanovinyl group of TMC278 and the aromatic side chain of Y183, which is facilitated by an ∼1.5 Å shift of the conserved Y 183 MDD motif. In the L100I/K103N RT/TMC278 structure, the binding mode of TMC278 is significantly altered so that the drug conforms to changes in the binding pocket primarily caused by the L100I mutation. The flexible binding pocket acts as a molecular “shrink wrap” that makes a shape complementary to the optimized TMC278 in wild-type and drug-resistant forms of HIV-1 RT. The crystal structures provide a better understanding of how the flexibility of an inhibitor can compensate for drug-resistance mutations.

6 November 2004 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PJPaul A. J. Janssen
Paul A. J. Janssen
PLPaul J. Lewi
Paul J. Lewi
EAEddy Arnold
Eddy Arnold
FDFrits Daeyaert
Frits Daeyaert
MJMarc de Jonge
Marc de Jonge
PSPaul Stoffels·
Paul Stoffels·

11 April 2010 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
KDKalyan Das
Kalyan Das
JAJames M Aramini
James M Aramini
LMLi-Chung Ma
Li-Chung Ma
RKRobert M Krug
Robert M Krug
EAEddy Arnold
Eddy Arnold